Albert F. Lobuglio

Albert F. Lobuglio's AcademicInfluence.com Rankings

Albert F. Lobuglio

Philosophy

#8122

World Rank

#11445

Historical Rank

Logic

#5154

World Rank

#6529

Historical Rank

philosophy Degrees

Albert F. Lobuglio

Biology

#10965

World Rank

#14331

Historical Rank

Immunology

#697

World Rank

#719

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Albert F. Lobuglio's Degrees

Doctorate Medicine University of California, San Francisco
PhD Immunology Stanford University

Why Is Albert F. Lobuglio Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Albert F. Lobuglio's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. (1999) (893)
Role of hydrogen peroxide in neutrophil-mediated destruction of cultured endothelial cells. (1981) (565)
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. (1989) (545)
Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. (2001) (493)
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. (2004) (489)
Red Cells Coated with Immunoglobulin G: Binding and Sphering by Mononuclear Cells in Man (1967) (437)
Human Blood Monocytes: Stimulators of Granulocyte and Mononuclear Colony Formation in vitro (1972) (366)
Human immune response to monoclonal antibodies. (1994) (303)
Effects of corticosteroid therapy on human monocyte function. (1975) (246)
Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. (2000) (236)
The Small Heat Shock Protein αB-crystallin Is a Novel Inhibitor of TRAIL-induced Apoptosis That Suppresses the Activation of Caspase-3* (2005) (230)
Effects of corticosteroids on human monocyte function. (1974) (222)
Characterization of a messenger RNA polynucleotide vaccine vector. (1995) (219)
Nuclear Localization of KLF4 Is Associated with an Aggressive Phenotype in Early-Stage Breast Cancer (2004) (211)
A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. (2001) (208)
Expression of human endogenous retrovirus k envelope transcripts in human breast cancer. (2001) (174)
Human granulocyte generation of hydroxyl radical (1978) (168)
Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. (1997) (167)
Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. (2000) (161)
A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. (2000) (150)
CD16+ monocytes in patients with cancer: spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor. (1995) (149)
Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. (2003) (146)
Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. (2002) (145)
Immune response to a carcinoembryonic antigen polynucleotide vaccine. (1994) (144)
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. (2004) (140)
Cellular Model of Warburg Effect Identifies Tumor Promoting Function of UCP2 in Breast Cancer and Its Suppression by Genipin (2011) (137)
Recurrent read-through fusion transcripts in breast cancer (2014) (137)
Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response. (1988) (133)
Evidence for hydroxyl radical generation by human Monocytes. (1977) (132)
A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. (1995) (130)
A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. (2003) (129)
Selected strategies to augment polynucleotide immunization. (1996) (128)
Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. (1993) (125)
Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. (1994) (121)
Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. (1992) (119)
Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. (1996) (114)
A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. (2002) (110)
A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. (2002) (99)
A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo. (1995) (97)
Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration. (1999) (97)
Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects. (1988) (96)
Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody. (1991) (96)
Leukemic reticuloendotheliosis. A study of the origin of the malignant cell. (1975) (96)
The nature of the alpha-methyldopa red-cell antibody. (1967) (95)
Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes (2016) (94)
Immune thrombocytopenic purpura. Use of a 125I-labeled antihuman IgG monoclonal antibody to quantify platelet-bound IgG. (1983) (91)
Characterization of glass adherent human mononuclear cells. (1973) (89)
A potential role for hypochlorous acid in granulocyte-mediated tumor cell cytotoxicity. (1980) (88)
Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. (2006) (87)
Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. (2001) (86)
An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. (1985) (85)
An oxygen-dependent mechanism of neutrophil-mediated cytotoxicity. (1980) (84)
Drug therapy of autoimmune hemolytic anemia. (1976) (83)
Phagocyte-generated oxygen metabolites and cellular injury. (1982) (81)
Human monocyte, lymphocyte, and granulocyte antibody-dependent cell-mediated cytotoxicity toward tumor cells. I. General characteristics of cytolysis. (1979) (80)
Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine. (2000) (79)
A carcinoembryonic antigen polynucleotide vaccine for human clinical use. (1995) (77)
Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. (1992) (76)
Effect of Niclosamide on Basal-like Breast Cancers (2014) (74)
Immunologic specificity of transfer factor. (1974) (73)
Alterations in hexose monophosphate shunt during lymphoblastic transformation. (1974) (72)
Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses. (1988) (71)
Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy. (2002) (71)
Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen. (1987) (70)
Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function. (2006) (67)
Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer. (1999) (67)
Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. (2001) (66)
ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas (2004) (66)
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. (2005) (66)
Human monocyte antibody-dependent cell-mediated cytotoxicity to tumor cells. (1978) (65)
Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. (1996) (63)
Oxidative mechanisms of monocyte-mediated cytotoxicity. (1980) (63)
Cetuximab Augments Cytotoxicity with Poly (ADP-Ribose) Polymerase Inhibition in Head and Neck Cancer (2011) (61)
Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. (1993) (59)
Polynucleotide-mediated immunization therapy of cancer. (1996) (59)
Human monocyte cytotoxicity to tumor cells. I. Antibody-dependent cytotoxicity. (1978) (58)
Decreased Serum B12 Levels With Oral Contraceptive Use (1972) (57)
Phase I Trial of an Anti‐CD19 Deglycosylated Ricin A Chain Immunotoxin in Non‐Hodgkin's Lymphoma: Effect of an Intensive Schedule of Administration (1995) (56)
Ultrastructural analysis of human natural killer cell activation. (1987) (53)
HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair. (2012) (52)
Phase I Study of the Intratumoral Administration of Recombinant Canarypox Viruses Expressing B7.1 and Interleukin 12 in Patients with Metastatic Melanoma (2005) (50)
Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. (2007) (50)
Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer. (1995) (49)
Phase I Study of a Plasmid DNA Vaccine Encoding MART-1 in Patients with Resected Melanoma at Risk for Relapse (2005) (49)
Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome. (1990) (48)
Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma (2013) (47)
Colchicine therapy for refractory idiopathic thrombocytopenic purpura. (1984) (47)
History of antibody therapy for non-Hodgkin's lymphoma. (2003) (46)
Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas. (1994) (46)
TRAIL receptor-targeted therapy. (2006) (44)
Characterization of poliovirus replicons encoding carcinoembryonic antigen. (1994) (44)
TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth (2007) (42)
Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. (2005) (42)
Transfer factor: isolation of a biologically active component. (1973) (41)
The effect of transfer factor therapy on tumor immunity in alveolar soft part sarcoma. (1973) (40)
Immune function of successfully treated lymphoma patients. (1976) (40)
Evidence for the elevation of serum carcinoembryonic antigen and tumor-associated glycoprotein-72 levels in patients administered interferons. (1991) (39)
Quantification of platelet-bound IgG by 125I-Staphylococcal protein A in immune thrombocytopenic purpura and other thrombocytopenic disorders. (1984) (38)
Brief Overview of Preclinical and Clinical Studies in the Development of Intraperitoneal Radioimmunotherapy for Ovarian Cancer (2007) (37)
Epithelial transformation by KLF4 requires Notch1 but not canonical Notch1 signaling (2009) (37)
Human lymphocyte, monocyte, and neutrophil antibody-dependent cell-mediated cytotoxicity toward human erythrocytes. (1978) (36)
Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen. (1998) (36)
Treatment of Human Colon Cancer Xenografts with TRA-8 Anti-death Receptor 5 Antibody Alone or in Combination with CPT-11 (2008) (34)
Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein. (2005) (33)
A novel monoclonal antibody design for radioimmunotherapy. (2003) (33)
Juvenile "congenital" pernicious anemia. Clinical and immunologic studies. (1966) (33)
Phase I study of anti-epidermal growth factor receptor (anti-EGFR) antibody C225 in combination with irradiation in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) (1998) (32)
The effect of tuberculosis and neoplasia on human monocyte staphylocidal activity. (1975) (32)
Monocyte-mediated antibody-dependent cell-mediated cytotoxicity: the role of the metabolic burst. (1981) (31)
TRAIL-receptor antibodies as a potential cancer treatment. (2007) (31)
A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1. (1993) (30)
Hedgehog Pathway Expression in Heterogeneous Pancreatic Adenocarcinoma: Implications for the Molecular Analysis of Clinically Available Biopsies (2007) (30)
Advances in monoclonal antibody therapy of cancer. (1992) (30)
Phase I clinical trial of CO17-1A monoclonal antibody. (1986) (30)
Measurement of Platelet Surface‐Bound IgG by a Monoclonal 125I‐Anti‐IgG Assay (1986) (29)
Recent progress in radioimmunotherapy for cancer. (1997) (29)
Platelet surface-bound IgG in patients with immune and nonimmune thrombocytopenia. (1987) (29)
Human lymphocyte antibody-dependent cell-mediated cytotoxicity (ADCC) toward human red blood cells. (1978) (28)
Intraperitoneal Pretarget Radioimmunotherapy with CC49 Fusion Protein (2005) (28)
Radioimmunoassay of free β-subunit of human chorionic gonadotropin as a prognostic test for persistent trophoblastic disease in molar pregnancy (1986) (28)
Induction of anti‐tumor immunity by intrasplenic administration of a carcinoembryonic antigen DNA vaccine (2000) (27)
Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity (2012) (27)
Sarcoid lymphocytes: spontaneous transformation and release of macrophage migration inhibition activity. (1976) (27)
Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration. (2005) (26)
A review of transfer factor immunotherapy in cancer (1974) (26)
CD 16 + Monocytes in Patients With Cancer : Spontaneous Elevation and Pharmacologic Induction by Recombinant Human Macrophage Colony-Stimulating Factor (2000) (25)
Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. (1995) (25)
Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region. (2005) (24)
Monocyte-platelet interaction in immune and nonimmune thrombocytopenia. (1989) (24)
Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials. (1997) (24)
A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer. (1993) (23)
SARCOID LYMPHOCYTES: B‐ AND T‐CELL QUANTITATION (1976) (22)
Human monocyte killing of Staphylococcus aureus: modulation by agonists of cyclic adenosine 3',5'-monophosphate and cyclic guanosine 3',5'-monophosphate (1979) (22)
In vivo treatment with a monoclonal chimeric anti‐CD4 antibody results in prolonged depletion of circulating CD4+ cells in chimpanzees (1993) (22)
Chemotherapy of intermediate- and high-grade non-Hodgkin's lymphomas with a high-dose doxorubicin-containing regimen. (1990) (21)
Editorial: Leukemic reticuloendotheliosis: a defined syndrome of an ill defined cell. (1976) (21)
Effect of TRA-8 Anti-Death Receptor 5 Antibody in Combination With Chemotherapy in an Ex Vivo Human Ovarian Cancer Model (2009) (20)
Phytomitogen- and antigen-induced blast transformation of feline lymphocytes. (1975) (20)
PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers (2015) (20)
A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma. (2006) (20)
HUMAN IMMUNE RESPONSE TO CARCINOEMBRYONIC ANTIGEN TUMOR VACCINES (1995) (19)
A migration inhibition-factor assay for tumor immunity in man. (1973) (19)
Direct quantitation of IgG subclasses 1, 2, and 3 bound to red cells by Rh1 (D) antibodies (1988) (18)
Clustered IgG on human red blood cell membranes may promote human lymphocyte antibody-dependent cell-mediated cytotoxicity. (1980) (18)
Platelet surface-bound IgG in patients with immune and nonimmune thrombocytopenia (1987) (18)
Clinical use of a standard kit-preparation of radiolabeled monoclonal antibody 96.5 in the diagnostic imaging of metastatic melanoma. (1988) (18)
Griffonia simplicifolia I lectin mediates macrophage-induced cytotoxicity against Ehrlich ascites tumor. (1982) (18)
Combination chemotherapy of refractory lymphoma with cis‐dichlorodiamineplatinum, vinblastine, and bleomycin (1982) (17)
Comparison of diagnostic and therapeutic doses of 131I-LYM-1 in patients with non-Hodgkin's lymphoma (1993) (17)
Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma (2007) (17)
Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid cells. (1998) (16)
Immune Hemolytic anemia. (1980) (16)
Re-examination of the EA rosette assay (Ripley) for Fc receptor leucocytes. (1979) (16)
Comparison of two mouse/human chimeric antibodies in patients with metastatic colon cancer (1992) (16)
Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy. (2003) (15)
Human monocyte glucose metabolism in lymphoma. (1977) (14)
The monocyte: new concepts of function. (1973) (14)
Decreased serum B 12 levels with oral contraceptive use. (1972) (14)
Neoantigen response in patients successfully treated for lymphoma. A Southwest Oncology Group study. (1979) (13)
Phytohemagglutinin (PHA) skin test in patients with sarcoidosis. (1975) (13)
An Oxygen-Dependent Mechanism of Neutrophil-Mediated Cytotoxicity (1980) (13)
Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer. (2012) (13)
Human lymphocyte and monocyte lysis of tumor cells mediated by a mouse/human IgG1 chimeric monoclonal antibody. (1988) (12)
Effect of intravenous gammaglobulin on circulating and platelet-bound antibody in immune thrombocytopenia (1989) (12)
Effect of human immune response on repeat courses of 131-chimeric B72.3 antibody therapy (1993) (12)
Monoclonal antibody therapy of cancer. (1992) (12)
Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer. (1995) (12)
Etretinate therapy for psoriasis. Reduction of antibody-dependent cell-mediated cytotoxicity of polymorphonuclear leukocytes. (1985) (12)
Treatment of hypercalcemia associated with malignancy. (1978) (12)
Skin test conversion following transfer factor. A double-blinded study of normal individuals. (1978) (11)
Quantitative assay of a human monoclonal IgM antibody (HA-1A) in human serum. (1989) (11)
Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition (2014) (11)
Identification of hypoxanthine as the major compoenet of a chromatographic fraction of transfer factor. (1976) (10)
Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma. (2011) (10)
Human monocyte interaction with antibody‐coated platelets. I. General characteristics (1984) (10)
SEREX analysis for tumor antigen identification in a mouse model of adenocarcinoma (2000) (10)
High-dose adriamycin combination chemotherapy for intermediate and high-grade non-Hodgkin's lymphomas. (1985) (10)
Transfer factor: a potential agent for cancer therapy. (1976) (10)
Impact of Rituximab Treatment on 90Y-Ibritumomab Dosimetry for Patients with Non-Hodgkin Lymphoma (2010) (10)
Comparison of methods for predicting myelotoxicity for non-marrow targeting I-131-antibody therapy. (2003) (9)
Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: a phase I study. (1994) (9)
Pharmacokinetics of a Mouse/Human Chimeric Monoclonal Antibody (C-17-1 A) in Metastatic Adenocarcinoma Patients (1990) (9)
A Method to Correct for Radioactivity in Large Vessels That Overlap the Spine in Imaging-Based Marrow Dosimetry of Lumbar Vertebrae (2008) (9)
Frequent anti-V-region immune response to mouse B72.3 monoclonal antibody (1992) (9)
Phase 1 trial of a novel anti-CD 20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma (2004) (8)
A non-invasive approach for monitoring breast tumor cells during therapeutic intervention. (2002) (8)
Comparison of monocyte and alveolar macrophage antibody-dependent cellular cytotoxicity and Fc-receptor activity. (1981) (8)
Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non-small cell lung cancer: clinical effects and hematologic toxicity. (2003) (8)
Phase I Trial of the Murine Monoclonal Anti-GD 2 Antibody 14 G 2 a in Metastatic Melanoma 1 (2006) (8)
Development and characterization of a monoclonal antibody to human embryonal carcinoma. (1987) (7)
Immune thrombocytopenia: effects of maternal gamma globulin infusion on maternal and fetal serum, platelet, and monocyte IgG. (1987) (7)
Study of the malarial parasite-red cell relationship with the use of a new immunologic marker. (1971) (7)
Radioimmunoscintigraphic detection of occult gestational choriocarcinoma. (1987) (7)
Normal human monocytes inhibit tumor cell growth in vitro. (1978) (6)
Lack of T-cell immunity in humans with preexisting anti-mouse immunoglobulin reactivity. (1992) (6)
Human monocyte metabolism: male vs. female. (1975) (6)
IDENTIFICATION OF HYPOXANTHINE AS THE MAJOR COMPONENT OF CHROMATOGRAPHICALLY PREPARED TRANSFER FACTOR (1976) (6)
Interaction of monocytes with tumor cells coated with complement with or without antibody. (1980) (6)
Correlation of prognostic factors and blood lymphocyte subtypes in non‐Hodgkin's lymphoma (1980) (5)
Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy. (2006) (5)
Effect of mouse anti-I region antiserum and complement on human mononuclear cell response to concanavalin A. (1982) (5)
Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity. (2006) (5)
Etretinate therapy and immune activities. (1986) (5)
Quinidine-induced immune thrombocytopenia. (1989) (5)
Radioimmunotherapy of colon cancer with an improved humanized monoclonal antibody design (2002) (5)
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer (2020) (5)
Human Monocyte Antibody-Dependent Cell-Mediated (1978) (5)
Phagocytosis of technetium-99m sulfur colloid by human polymorphonuclear leukocytes. (1978) (4)
Effect of intravenous gammaglobulin on circulating and platelet-bound antibody in immune thrombocytopenia. (1989) (4)
Detection of human anti-murine antibody (HAMA) following infusion of Oncoscint® CR103 : comparison of Immustrip® ELISA with a double antigen radiometric assay (1991) (4)
ln-111 Labeled Monoclonal Anti-Carcinoembryonic Antigen Antibody (ZCE025) in the Immunoscintigraphlc Imaging of Metastatic Antigen-Producing Adenocarcinomas (1991) (4)
Chimeric antibodies. (1993) (4)
Phase II trial of Baker's antifol in metastatic renal cell carcinoma: a Southwest Oncology Group Study. (1980) (4)
Long Term Outcome of Intraperitoneal Radioimmunotherapy for Ovarian Cancer (2008) (4)
Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma. (2013) (3)
Transfer-factor therapy of malignancy. (1974) (3)
Leukopenia -- a new immune mechanism. (1976) (3)
radioimmunotherapy for B-cell non-Hodgkin's lymphoma Phase I trial of a novel anti-CD20 fusion protein in pretargeted (2013) (3)
Testicular uptake and radiation dose in patients receiving Zevalin and Pretarget CC49Fusion protein. (2005) (3)
Genetic Immunotherapy Approaches (2005) (3)
Immunoperoxidase staining of early human melanoma colonies with monoclonal antibodies. A new method for in vitro antigenic-morphologic correlation. (1984) (3)
MHC II antigen presentation pathway expression in triple-negative breast cancer. (2015) (3)
Chimeric antibodies with specificity for tumor antigens: demonstration of in situ localization to tumors after antibody therapy. (1998) (3)
Lymphocyte sensitivity and cellular immunity in neoplasia. (1973) (3)
Human tumor-specific immunity--has it "arrived"? (1993) (2)
Transfer factor: Potential for therapy of malignant diseases. (1975) (2)
TBCRC 002: A phase II, randomized, open label trial of preoperative letrozole versus letrozole (LET) in combination with bevacizumab (BEV) in post-menopausal women with newly diagnosed stage II/III breast cancer. (2013) (2)
Susceptibility of HER2+ breast cancer cells to poly (ADP-ribose) polymerase (PARP) inhibition independent of an inherent DNA repair defect. (2012) (2)
Fractionated radioimmunotherapy FOR PATIENTS WITH CHEMOTHERAPY-RESISTANT NON-HODGKINS LYMPHOMA (NHL) (1992) (2)
A Pilot Trial of Pre-Operative (Neoadjuvant) Letrozole in Combination with Bevacizumab in Post-Menopausal Women with Newly Diagnosed Estrogen and/or Progesterone Receptor Positive Breast Cancer. (2009) (2)
Clinical Experience with Murine, Human and Genetically Engineered Monoclonal Antibodies (1994) (2)
Effects of Adjuvant Chelator or Chemotherapy on Dosimetry of 90Y-CC49 in Lung Cancer Patients Using 111In-CC49 as a Tracer (2004) (2)
Brentuximab Vedotin (SGN-35) for CD30-Positive Malignancies (2013) (2)
The expression of class II major histocompatibility molecules on breast tumors delays T cell exhaustion, expands the T cell repertoire and slows tumor growth (2018) (2)
Targeting of 125I-Labeled B Lymphocyte Stimulator (2003) (2)
Synthetic Lethal Interactions Between EGFR and PARP Inhibition in Triple Negative Breast Cancer (2012) (1)
INTRATUMORAL INJECTION OF A CANARYPOX VIRUS ENCODING HUMAN (ALVAC-IL-12) IN MELANOMA PATIENTS: RESULTS OF A PHASE Ib TRIAL (1999) (1)
Human Immune Respone to Monoclonal Antibodies (1994) (1)
CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE) (2013) (1)
Phase 1 study of an anti-GD3 monoclonal antibody, (KW-2871) in patients with advanced metastatic melanoma (2005) (1)
Immune response to L2 guinea pig leukemia-specific antigens. (1977) (1)
2125 Enhanced intraperitoneal radioimmunotherapy with adjuvant Interferon and Taxol (1997) (1)
THE ABILITY OF THE LATEX-BINDING LYMPHOCYTE ASSAY TO PREDICT IN VIVO EFFICACY OF ANTILYMPHOCYTE SERA (1972) (1)
Radioimmunotherapy for metastatic prostate cancer using a high affinity antibody (1993) (1)
Abstract P1-12-04: Long Term Follow-Up of a Pilot Trial of Pre-Operative (Neoadjuvant) Letrozole in Combination with Bevacizumab in Post-Menopausal Women with Newly Diagnosed Estrogen and/or Progesterone Receptor Positive Breast Cancer (2010) (1)
503 Phase I radioimmunotherapy (RIT) study of 90Y-CC49 monoclonal antibody (MAb) therapy in patients with advanced non-small cell lung cancer (NSCLC) (1997) (1)
LOW V-REGION IMMUNOGENICITY OF THERAPEUTIC DOSES OF 131I-LL2 MOUSE MONOCLONAL ANTIBODY IN LYMPHOMA PATIENTS (1994) (1)
Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer. (2009) (1)
Long-term follow-up of dose-dense neoadjuvant chemotherapy in patients with stage II/III breast cancer. (2011) (1)
Alternated versus syncopated CHOP-PVB: two studies for the treatment of non-Hodgkin's lymphoma by the Southwest Oncology Group. (1991) (1)
Oxidative mechanisms of monocyte-mediated cytotoxicity ( phorbol myristate acetate / leukocytes / hydrogen peroxide / superoxide anion / superoxide dismutase ) (2003) (1)
Human Monocyte Cytotoxicity to Tumor Cells (1978) (1)
Effect of TRA-8 anti-DR5 monoclonal antibody in combination with chemotherapy in an ex vivo human ovarian cancer model (2008) (1)
Treatment of metastatic colon cancer with fractionated dosing of radiolabeled monoclonal antibodies (1991) (1)
An animal model to predict the immunogenicity of murine V regions in humans. (1993) (1)
antibodies anti-DR5 combinations and anti-DR4 antibodies and other therapeutic agents (2002) (0)
Traitement de cancers a genotype de type basal (2010) (0)
Phase I T rial o f t he A nti-Lewis Y D rug I mmunoconjugate BR96-Doxorubicin i n P atients W ith L ewis Y -Expressing Epithelial T umors (2000) (0)
Therapeutics , Targets , and Chemical Biology HER 2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair (2012) (0)
Abstract 4030: Epigenetic induction of MHC-II pathway expression in murine ovarian cancer cell line (2016) (0)
Abstract P1-15-02: Long term follow-up of the neo-adjuvant pilot trial evaluating activity of letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed estrogen and/or progesterone receptor positive primary breast cancer (2013) (0)
Abstract P4-11-04: The Influence of Radiation on Survival in Patients with Triple Negative Stage II Breast Cancer (2010) (0)
2761 – A NEW ASSAY FOR ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) BY HUMAN LYMPHOCYTES (Ly), MONOCYTES (Mo) AND NEUTROPHILS (Ne) (1978) (0)
Comparative dosimetry with repeat courses of 131I-labeled murine or mouse/human chimeric monoclonal antibodies (1990) (0)
Protein in Patients with Gastrointestinal Malignancies Patient-Specific Dosimetry of Pretargeted Radioimmunotherapy Using CC 49 Fusion (2005) (0)
Prediction of in vivo efficacy of antilymphocyte sera (ALS) by a new in vitro assay. (1971) (0)
189 PHASE 1 STUDY OF AN ANTI-GD3 MONOCLONAL ANTIBODY (KW-2871) IN PATIENTS WITH ADVANCED METASTATIC MELANOMA. (2006) (0)
UAB-Community Breast Cancer Network (2002) (0)
PHARMACOKINETICS AND IMMUNE RESPONSE OF 177LU-CC49 MONOCLONAL ANTIBODY IN PATIENTS WITH RECURRENT OR PERSISTENT OVARIAN CANCER (1994) (0)
Abstract P5-10-19: The Influence of Time to Completion of Chemotherapy on Survival in Patients with Triple Negative Stage III Breast Cancer (2010) (0)
Treatment of a B-Cell, Primary Central Nervous System Lymphoma Patient with Radioimmunotherapy Using Zevalin®: A Proof-of-Principal Case. (2004) (0)
Monocyte antibody dependent cellular cyto toxicity to red blood cell targets competitive inhibition with immuno globulin g and immuno globulin g subclasses (1980) (0)
Phase I Clinical and Pharmacological Study of Suppression of Human Antimouse Antibody Response to Monoclonal Antibody L 6 by Deoxyspergualin 1 (2006) (0)
POLYNUCLEOTIDE IMMUNIZATION TO CEA VIA INTRAMUSCULAR INJECTION OR CUTANEOUS PARTICLE BOMBARDMENT (1995) (0)
Technetium 99m labelling of corynebacterium parvum for study of tissue localization (1976) (0)
Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody in prostate cancer (2002) (0)
Impact of Full Dose of Rituximab on Pharmacokinetics and Dosimetry of Zevalin for Patients with Non-Hodgkin’s Lymphoma (2005) (0)
Relevance of chemotherapy in gastrointestinal cancer. (1988) (0)
IDENTIFICATION OF NOVEL TUMOR ASSOCIATED ANTIGENS IN MELANOMA PATIENTS RECEIVING ALVAC-IL-12 (1999) (0)
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer (2020) (0)
Phase I, Multicenter, Open Label, Dose Escalation of 90 yttrium-Ibritumomab Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+ B-Cell Lymphoma (2011) (0)
Abstract 4684: Synthetic lethal interaction between EGFR and PARP inhibition (2012) (0)
2105 Phase 1 trial of intraperitoneal radioimmunotherapy for ovarian cancer (1996) (0)
Genetic insights into Warburg Effect reveal tumor promoting function of UCP2 (2011) (0)
PROGRESS IN HEMATOLOGY, Vol. VI (1970) (0)
Expression levels of PARP1 and phospho-p65 protein in human HER2-positive breast cancers. (2015) (0)
Impact of rituximab treatment on Y-90-Zevalin dosimetry for patients with non-Hodgkin's lymphoma (2007) (0)
A Preliminary Report of a Phase I Study of Zevalin® Using a Modified Treatment Regimen for Relapsed or Refractory CD20+ B-Cell Follicular or Transformed Non-Hodgkin’s Lymphoma (NHL). (2005) (0)
Detection of disseminated breast cancer growth and treatment response using non-invasive bioluminescence imaging. (2004) (0)
Abstract B37: Increased expression of poly (ADP-ribose) polymerase (PARP) and phospho-p65 in human HER2+ breast cancer (2013) (0)
Crosstalk between PARP-1 and NF-κB signaling pathways as a potential determinant of PARPi sensitivity in trastuzumab resistant HER2+ breast cancer cell lines. (2015) (0)
Erratum: Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region (Cancer Biotherapy and Radiopharmaceuticals (2005) 20, 5 (502-513)) (2005) (0)
Limited sampling models for HA-1A IgM monoclonal antibody. (1990) (0)
Invited commentary: targeting of 125I-labeled B lymphocyte stimulator. (2003) (0)
EVIDENCE THAT RECOMBINANT INTERFERONS CAN ENHANCE THE SENSITIVITY OF THE DETECTION OF SERUM TAG-72 AND CEA IN PATIENTS DIAGNOSED WITH ADENOCARCINOMA (1992) (0)
Biodistribution and Clearance of In-111/Y-90-IDEC-159 in Patients with Metastatic Colorectal Adenocarcinoma (2010) (0)
Human HER2+ Breast Cancer Susceptibility to Poly(ADP-Ribose) Polymerase Inhibitors Independent of a Homologous Recombination Repair Defect (2012) (0)
Abstract LB-260: Sensitivity of breast cancer stem cells to TRA-8 anti-DR5 monoclonal antibody (2010) (0)
A new tumour marker for early detection of subclinical metastatic melanoma (2004) (0)
Abstract 865: Inhibition of Wnt co-receptor LRP6 sensitizes basal-like breast cancer stem cells to TRA-8 anti-DR5 monoclonal antibody. (2013) (0)
L2C leukemia: a model of human acute leukemia. (1977) (0)
Survival predictors of intraperitoneal radioimmunotherapy for ovarian cancer (2011) (0)
RITUXANTM/CHOP CHEMO IMMUNOTHERAPY IN PATIENTS WITH LOW-GRADE OR FOLLICULAR (LG/F) NON-HODGKINʼS LYMPHOMA (NHL) (1997) (0)
IMMUNOGENICITY OF CHIMERIC MOUSE/HUMAN MONOCLONAL ANTIBODIES (1993) (0)
Dendritic Cell Vaccine Therapy for Breast Cancer Micro-Metastases. (1995) (0)
Intraperitoneal radioimmunotherapy for ovarian cancer: results of a phase i study with high affinity monoclonal antibody (1994) (0)
Phase I Clinical and Pharmacological Study of Suppression of Human Antimouse Antibody Response to Monoclonal Antibody L6 by Deoxyspergualin1 (2006) (0)
Treatment o f P atients W ith L ow-Grade B -Cell L ymphoma With t he C ombination o f C himeric A nti-CD20 M onoclonal Antibody a nd C HOP C hemotherapy (1999) (0)
Safety and Immunogenicity of a DNA Vaccine Encoding Carcinoembryonic Antigen and Hepatitis B Surface Antigen in Colorectal Carcinoma Patients 1 (2002) (0)
AN ANIMAL MODEL TO PREDICT THE IMMUNOGENICITY OF MURINE V-REGIONS IN MAN (1993) (0)
Abstract 1461: MHCII-expressing breast cancer cells can induce anti-tumor immune response (2016) (0)
Correlation between poly (ADP-ribose) polymerase (PARP) and phospho-p65 expression in human breast cancer. (2013) (0)
PO-487 Prognosis of triple negative breast cancer is associated with MHC II genes (2018) (0)
oubie-blinded study of normal indivi (1978) (0)
IMMUNE RESPONSE TO INTRAMUSCULAR OR INTRAVENOUS CEA POLYNUCLEOTIDE IMMUNIZATION IN LARGE ANIMAL MODELS (1995) (0)
Recent major breakthrough announced by U-M's growing clinical research faculty. (1981) (0)
Abstract 5496: Cetuximab induces synthetic lethality with the poly (ADP-Ribose) polymerase (PARP) inhibitor ABT-888 in head and neck cancer (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Albert F. Lobuglio?

Albert F. Lobuglio is affiliated with the following schools:

Albert F. Lobuglio's Academic­Influence.com Rankings

Albert F. Lobuglio's Degrees

Why Is Albert F. Lobuglio Influential?

Albert F. Lobuglio's Published Works

Published Works

What Schools Are Affiliated With Albert F. Lobuglio?

Albert F. Lobuglio's AcademicInfluence.com Rankings